芦可替尼用于治疗成人斯蒂尔病并发的难治性巨噬细胞活化综合征。
Ruxolitinib for Refractory Macrophage Activation Syndrome Complicating Adult-Onset Still's Disease.
作者信息
Levy Ofer, Apel Arie, Alhdor Hossam, Mizrachi Avraham, Agmon-Levin Nancy, Koren-Michowitz Maya, Amit-Vazina Mirit
机构信息
Shamir Medical Center, Internal Medicine B, Rheumatology Unit, Zerifin, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Shamir Medical Center, Department of Hematology, Zerifin, Israel.
出版信息
Eur J Rheumatol. 2022 Oct;9(4):217-220. doi: 10.5152/eurjrheum.2022.21064.
Abstract
Macrophage activation syndrome is the most frequent life-threatening complication of adult-onset Still's disease. This is a nearly fatal case of a young patient, which has been refractory to corticoste- roids, anakinra, tocilizumab, cyclosporine A, and etoposide, but eventually responded miraculously to salvage therapy with ruxolitinib. We review recent pertinent data related to the therapeutic value of ruxolitinib for macrophage activation syndrome triggered by adult-onset Still's disease.
摘要
巨噬细胞活化综合征是成人斯蒂尔病最常见的危及生命的并发症。这是一名年轻患者的近乎致命的病例，该病例对皮质类固醇、阿那白滞素、托珠单抗、环孢素A和依托泊苷均无反应，但最终对鲁索替尼挽救治疗产生了奇迹般的反应。我们回顾了与鲁索替尼治疗成人斯蒂尔病引发的巨噬细胞活化综合征的治疗价值相关的近期相关数据。
相似文献
1
Ruxolitinib for Refractory Macrophage Activation Syndrome Complicating Adult-Onset Still's Disease.
Eur J Rheumatol. 2022 Oct;9(4):217-220. doi: 10.5152/eurjrheum.2022.21064.
2
Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still's disease: when dosage matters in overcoming secondary therapy resistance.
Ther Adv Musculoskelet Dis. 2020 Nov 24;12:1759720X20974858. doi: 10.1177/1759720X20974858. eCollection 2020.
3
Macrophage activation syndrome complicating adult onset Still's disease: A single center case series and comparison with literature.
Semin Arthritis Rheum. 2016 Jun;45(6):711-6. doi: 10.1016/j.semarthrit.2015.11.002. Epub 2015 Nov 10.
4
A Case of Macrophage Activation Syndrome During the Treatment of Adult-onset Still's Disease With Tocilizumab.
J Rheum Dis. 2022 Apr 1;29(2):123-128. doi: 10.4078/jrd.2022.29.2.123.
5
Successful use of short-term add-on tocilizumab for refractory adult-onset still's disease with macrophage activation syndrome despite treatment with high-dose glucocorticoids, cyclosporine, and etoposide.
Mod Rheumatol Case Rep. 2020 Jul;4(2):202-207. doi: 10.1080/24725625.2020.1741073. Epub 2020 Mar 23.
6
Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still's disease.
Joint Bone Spine. 2013 Dec;80(6):653-5. doi: 10.1016/j.jbspin.2013.04.011. Epub 2013 Jun 7.
7
Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease Successfully Treated with Anakinra.
Case Rep Rheumatol. 2016;2016:3717392. doi: 10.1155/2016/3717392. Epub 2016 Oct 12.
8
Rescued from desperation: adult-onset Still's disease with life-threatening interstitial lung disease and macrophage activation : Successful treatment by Tocilizumab.
Z Rheumatol. 2022 May;81(4):335-338. doi: 10.1007/s00393-021-01063-7. Epub 2021 Aug 10.
9
Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still's disease.
Expert Opin Biol Ther. 2022 Jan;22(1):79-85. doi: 10.1080/14712598.2021.1942832. Epub 2021 Jun 24.
10
Short-term, low-dose etoposide in refractory adult-onset Still's disease-associated macrophage activation syndrome.
Clin Rheumatol. 2022 Sep;41(9):2817-2823. doi: 10.1007/s10067-022-06184-1. Epub 2022 May 19.
引用本文的文献
1
Efficacy and safety of ruxolitinib in adult patients with refractory rheumatic disease-associated macrophage activation syndrome.
Front Immunol. 2025 Jun 26;16:1604648. doi: 10.3389/fimmu.2025.1604648. eCollection 2025.
2
Macrophage activation syndrome-associated adult onset Still disease treatment: a scoping review of case reports and case series.
Proc (Bayl Univ Med Cent). 2025 Apr 1;38(4):499-511. doi: 10.1080/08998280.2025.2482315. eCollection 2025.
3
Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease.
Ann Rheum Dis. 2024 Nov 14;83(12):1731-1747. doi: 10.1136/ard-2024-225854.
4
JAK Inhibitors in Cytokine Storm Syndromes.
Adv Exp Med Biol. 2024;1448:583-600. doi: 10.1007/978-3-031-59815-9_39.
5
Immunopathology of and potential therapeutics for secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome: a translational perspective.
Exp Mol Med. 2024 Mar;56(3):559-569. doi: 10.1038/s12276-024-01182-6. Epub 2024 Mar 6.
6
Advances in attractive therapeutic approach for macrophage activation syndrome in COVID-19.
Front Immunol. 2023 Jul 6;14:1200289. doi: 10.3389/fimmu.2023.1200289. eCollection 2023.
7
Rare complications of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: Time to nip them in the bud.
Front Immunol. 2022 Oct 6;13:1009546. doi: 10.3389/fimmu.2022.1009546. eCollection 2022.
本文引用的文献
1
Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome.
J Cancer Res Clin Oncol. 2020 Nov;146(11):3063-3074. doi: 10.1007/s00432-020-03301-y. Epub 2020 Jul 2.
2
Tofacitinib in refractory adult-onset Still's disease: 14 cases from a single centre in China.
Ann Rheum Dis. 2020 Jun;79(6):842-844. doi: 10.1136/annrheumdis-2019-216699. Epub 2020 Feb 20.
3
Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.
Lancet Haematol. 2019 Dec;6(12):e630-e637. doi: 10.1016/S2352-3026(19)30156-5. Epub 2019 Sep 16.
4
Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis.
Haematologica. 2020 May;105(5):e210-e212. doi: 10.3324/haematol.2019.222471. Epub 2019 Sep 12.
5
Macrophage activation syndrome complicating rheumatic diseases in adults: case-based review.
Rheumatol Int. 2020 Apr;40(4):663-669. doi: 10.1007/s00296-019-04393-7. Epub 2019 Jul 31.
6
Calming the storm in HLH.
Blood. 2019 Jul 11;134(2):103-104. doi: 10.1182/blood.2019001333.
7
Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis.
Blood. 2019 Jul 11;134(2):147-159. doi: 10.1182/blood.2019000761. Epub 2019 Apr 23.
8
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults.
Blood. 2019 Jun 6;133(23):2465-2477. doi: 10.1182/blood.2018894618. Epub 2019 Apr 16.
9
Treatment of refractory adult onset Still's disease with combination anakinra and baricitinib therapy.
Rheumatology (Oxford). 2019 Apr 1;58(4):736-737. doi: 10.1093/rheumatology/key414.
10
Complications of adult-onset Still's disease and their management.
Expert Rev Clin Immunol. 2018 May;14(5):351-365. doi: 10.1080/1744666X.2018.1465821. Epub 2018 Apr 26.
Zotero 插件